Advisors Asset Management Inc. cut its position in shares of Ionis Pharmaceuticals Inc. (NASDAQ:IONS) by 8.2% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 6,063 shares of the company’s stock after selling 545 shares during the period. Advisors Asset Management Inc.’s holdings in Ionis Pharmaceuticals were worth $141,000 as of its most recent filing with the SEC.
Several other institutional investors also recently made changes to their positions in the stock. Parametric Risk Advisors LLC bought a new position in shares of Ionis Pharmaceuticals during the first quarter worth about $106,000. Opera Trading Capital increased its position in Ionis Pharmaceuticals by 150.0% in the first quarter. Opera Trading Capital now owns 2,892 shares of the company’s stock valued at $117,000 after buying an additional 1,735 shares during the period. Rockefeller Financial Services Inc. acquired a new position in Ionis Pharmaceuticals during the second quarter valued at $114,000. Schonfeld Strategic Advisors LLC acquired a new position in Ionis Pharmaceuticals during the first quarter valued at $354,000. Finally, Commerzbank Aktiengesellschaft FI increased its position in Ionis Pharmaceuticals by 1.6% in the second quarter. Commerzbank Aktiengesellschaft FI now owns 8,966 shares of the company’s stock valued at $209,000 after buying an additional 140 shares during the period. Institutional investors and hedge funds own 89.58% of the company’s stock.
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) traded down 1.28% during midday trading on Friday, hitting $33.82. 682,991 shares of the company traded hands. The stock has a 50 day moving average price of $32.65 and a 200-day moving average price of $32.35. The company’s market cap is $4.09 billion. Ionis Pharmaceuticals Inc. has a 12-month low of $19.59 and a 12-month high of $65.34.
Ionis Pharmaceuticals (NASDAQ:IONS) last posted its quarterly earnings data on Tuesday, August 9th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.05. The business earned $38.50 million during the quarter, compared to the consensus estimate of $38.52 million. Ionis Pharmaceuticals had a negative net margin of 128.94% and a negative return on equity of 126.88%. The business’s revenue was down 68.0% compared to the same quarter last year. Analysts expect that Ionis Pharmaceuticals Inc. will post ($1.11) EPS for the current year.
Several equities analysts have weighed in on the stock. BMO Capital Markets upgraded shares of Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and raised their target price for the company from $42.00 to $48.00 in a report on Thursday. Janney Montgomery Scott assumed coverage on shares of Ionis Pharmaceuticals in a report on Wednesday, September 28th. They set a “buy” rating and a $47.00 target price for the company. Piper Jaffray Cos. restated an “overweight” rating and set a $46.00 target price on shares of Ionis Pharmaceuticals in a report on Monday, September 26th. Wells Fargo & Co. restated a “buy” rating on shares of Ionis Pharmaceuticals in a report on Sunday, September 11th. Finally, Cowen and Company restated a “market perform” rating on shares of Ionis Pharmaceuticals in a report on Saturday, August 13th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the stock. Ionis Pharmaceuticals presently has an average rating of “Hold” and an average price target of $42.92.
In other Ionis Pharmaceuticals news, COO B Lynne Parshall sold 12,500 shares of the business’s stock in a transaction dated Thursday, September 1st. The shares were sold at an average price of $29.88, for a total value of $373,500.00. Following the sale, the chief operating officer now directly owns 25,558 shares in the company, valued at $763,673.04. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman Stanley T. Crooke sold 22,000 shares of the business’s stock in a transaction dated Wednesday, September 21st. The stock was sold at an average price of $35.50, for a total transaction of $781,000.00. Following the completion of the sale, the chairman now owns 45,029 shares in the company, valued at $1,598,529.50. The disclosure for this sale can be found here. 1.86% of the stock is currently owned by corporate insiders.
Ionis Pharmaceuticals Company Profile
Ionis Pharmaceuticals, Inc, formerly Isis Pharmaceuticals, Inc, is engaged in discovering and developing ribonucleic acid-targeted (RNA-targeted) therapeutics. The Company operates through two segments: Ionis Core and Akcea Therapeutics. The Company’s Ionis Core segment is developing a drug discovery platform.
Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals Inc. (NASDAQ:IONS).
Receive News & Ratings for Ionis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.